Advertisement
Metsera, Inc. (MTSR) closed at $70.50 on NASDAQ in the United States on Mar 23 2026, ahead of its scheduled earnings release on Mar 25. MTSR stock has climbed sharply year-to-date, with a YTD gain of 166.04% and a 3‑month gain near 97.65%, making the upcoming report a likely volatility catalyst. Investors will watch guidance, cash runway and clinical updates for Metsera’s obesity and metabolic pipeline to gauge whether current valuation holds.
Metsera, Inc. (MTSR) trades on NASDAQ and closed at $70.50 with a one‑day change of -0.25 (-0.35%). Trading volume was 27,874,411.00 versus an average volume of 3,501,952.00, giving a relative volume of 7.96. The stock’s 50‑day average is $53.47 and the 200‑day average is $35.09, while the 52‑week range is $12.30 to $83.86. High volume and wide divergence from moving averages signal investor focus ahead of the earnings release.
Metsera reports earnings on Mar 25 2026 after market close, per the company schedule. The market will focus on clinical progress for MET‑097i and MET‑233i, cash burn and R&D cadence. Market detail on the earnings schedule is available from MarketBeat and the company site at Metsera. Clinical readouts or guidance changes could swing MTSR stock materially on release.
Metsera operates in Healthcare, industry Biotechnology, with 930 full‑time employees and a market cap of $7,429,021,325.00. Trailing EPS is -2.99 and TTM PE is -23.58, reflecting pre‑revenue clinical stage status. Key balance metrics include cash per share $4.27, book value per share $3.21, and a strong current ratio of 4.25, pointing to a multi‑quarter cash runway if burn remains controlled. Valuation multiples such as price‑to‑book at 21.96 reflect high investor growth expectations rather than earnings today.
Meyka AI rates MTSR with a score out of 100: 66.43 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. On technicals, short‑term indicators show ATR 0.65 and Keltner mid at 70.50, consistent with tight intraday ranges near current price. High trading volume versus average suggests event‑driven moves; investors should expect increased volatility into earnings. Meyka AI provides this as AI‑powered market analysis and not investment advice.
The primary opportunity is clinical success for Metsera’s obesity and diabetes candidates, which would justify current premium multiples. A positive readout or encouraging guidance could push MTSR stock well above recent highs. The main risks are clinical setbacks, regulatory delay, or unexpected cash burn that would pressure valuation. Additional risks include limited analyst coverage and the stock’s rapid run which may amplify short‑term swings.
Meyka AI’s forecast model projects a 1‑year price of $148.30, implying a potential upside of 77.83% from the current $70.50 level. The model also shows a 3‑year target of $297.56 and a 5‑year target of $447.33. These are scenario‑based projections reflecting successful clinical progression and market adoption. Forecasts are model‑based projections and not guarantees; they assume positive trial outcomes and steady funding.
Metsera (MTSR) enters its Mar 25, 2026 earnings window with $70.50 stock price, heavy volume and a clear clinical news dependence. Fundamentals show deep R&D investment, cash per share $4.27 and a strong current ratio of 4.25, but negative EPS -2.99 and high price‑to‑book 21.96 signal that returns depend on pipeline milestones. Meyka AI rates MTSR 66.43 (B, HOLD) and its model projects a 1‑year price of $148.30, an implied upside of 77.83% versus today. Investors should weigh event risk: a clean earnings and clinical update could validate the premium, while setbacks could prompt sharp downside. Our outlook frames MTSR stock as a binary clinical‑stage play with high volatility. Forecasts are models, not guarantees; do your own research and monitor the Mar 25 release closely.
When does Metsera report earnings and why does it matter for MTSR stock?
Metsera reports earnings on Mar 25 2026 after market close. The update matters because clinical progress, cash burn and guidance will likely move MTSR stock sharply in either direction.
What are the key financials investors should watch for MTSR stock?
Watch cash per share $4.27, operating cash flow metrics, R&D spending, and any guidance on runway. These items drive MTSR stock sentiment given the company’s clinical stage.
What is Meyka AI’s grade and what does it mean for MTSR stock?
Meyka AI rates MTSR 66.43 (B, HOLD). The grade reflects sector and benchmark comparisons, growth, metrics and forecasts. It is informational and not personalized advice.
What price targets and upside does the Meyka forecast show for MTSR stock?
Meyka AI projects a 1‑year price of $148.30 (about 77.83% upside from $70.50). The model also lists a 3‑year target near $297.56. Forecasts are projections, not guarantees.
Pick what interests you most and we will get you started.
Find more articles like this one
Ask our AI about any stock
Get daily updates and alerts (coming March 2026)
Pick what interests you most and we will get you started.
Find more articles like this one
Ask our AI about any stock
Get daily updates and alerts (coming March 2026)
Meyka is the best AI Powered Real-Time Stock and Crypto News Platform that helps investors make decisions based on Historical Data.
The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.
Quick view of what's moving in the market today.
